Document Detail

Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results.
MedLine Citation:
PMID:  15311027     Owner:  NLM     Status:  MEDLINE    
PURPOSE: We assessed the medium-term (3-year) efficacy of transurethral ethanol injection therapy of the prostate (EIP) for benign prostatic hyperplasia. MATERIALS AND METHODS: A total of 34 patients were followed for a median of 4.3 years after EIP. Mean age was 68.1 years and mean baseline prostate volume was 49.3 ml. With the patient under combined sacral and urethral anesthesia, dehydrated ethanol was injected into the prostate with endoscopic guidance. A urethral catheter was inserted postoperatively. RESULTS: Mean total ethanol dose was 6.4 ml and a catheter was required for a mean of 7.6 days postoperatively. Mean International Prostate Symptom Score was 21.8 points before EIP (in 34 patients), and decreased to 13.1 points after 3 years (in 17, p <0.01). Mean quality of life index decreased from 5.0 points before EIP to 2.8 points after 3 years (p <0.001). Mean peak urine flow rate was 8.3 ml per second before EIP and increased to 12.7 ml per second after 3 years (p <0.01). Mean residual urine volume decreased from 93 ml before EIP to 28 ml after 3 years (p <0.01). Mean prostate volume decreased from 49.3 ml before EIP to 45.7 ml after 1 year (p <0.001), but increased to 51.4 ml after 3 years. No major complications were experienced. By 3 years after surgery 59.0% of patients had not required further treatment. CONCLUSIONS: Transurethral EIP caused minimal complications while maintaining improvement of the prostate symptom score and an increased peak urine flow after 3 years.
Nobuyuki Goya; Nobuo Ishikawa; Fumio Ito; Chika Kobayashi; Yasuko Tomizawa; Hiroshi Toma
Related Documents :
7538237 - A controlled trial of bicalutamide versus flutamide, each in combination with luteinizi...
3176217 - Ketoconazole in initial management and treatment of metastatic prostate cancer to spine.
11241547 - A phase ii trial of estramustine and etoposide in hormone refractory prostate cancer: a...
10992367 - Impact of interventional therapy for benign prostatic hyperplasia on quality of life an...
10850577 - Effect of the administration of recombinant activated factor vii (rfviia; novoseven) in...
20847967 - Late outcomes following percutaneous coronary interventions: results from a large, obse...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of urology     Volume:  172     ISSN:  0022-5347     ISO Abbreviation:  J. Urol.     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-08-16     Completed Date:  2004-09-03     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1017-20     Citation Subset:  AIM; IM    
Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Ethanol / administration & dosage*,  adverse effects
Injections / adverse effects
Middle Aged
Prostatic Hyperplasia / drug therapy*
Quality of Life
Treatment Outcome
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resectio...
Next Document:  Clinical experiences with desmopressin for long-term treatment of nocturia.